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Introduction
============

The Bcl-2 family members Bax and Bak are crucial mediators of apoptosis during development and disease. Mice deficient in both proteins exert gross developmental defects and are not viable ([@bib31]; [@bib40]). Moreover, cells derived from these animals are resistant to numerous apoptotic stimuli, including overexpression of proapoptotic BH3-only proteins ([@bib7]; [@bib49]; [@bib30]). BH3-only proteins, which act as sensors of cellular stress, are activated by transcriptional up-regulation and/or posttranslational modification following an apoptotic stimulus ([@bib39]). Once activated, these proteins translocate to mitochondria inducing the activation of Bax/Bak by yet unknown mechanisms ([@bib14]; [@bib3]; [@bib7]; [@bib30]; [@bib34]). As a consequence, Bax and Bak form oligomeric pores ([@bib19]; [@bib1], [@bib2]) leading to the release of apoptogenic factors from mitochondria into the cytosol ([@bib26]; [@bib41]; [@bib9]).

Both Bax and Bak are tail anchored in the mitochondrial outer membrane (MOM) via a COOH-terminal hydrophobic transmembrane domain that is followed by basic residues ([@bib50]; [@bib18]; [@bib36]; [@bib46]; [@bib10]). Bak constitutively localizes to the MOM where, following an apoptotic stimulus, it is activated by conformational change and/or relieved from inhibitory proteins ([@bib19]). In contrast, Bax resides primarily in the cytosol and requires an initial activation step to promote its translocation to the MOM ([@bib50]; [@bib18]; [@bib20]; [@bib24]; [@bib5]). The solution structure of Bax revealed that its transmembrane region (TMB) is folded back into a hydrophobic pocket formed by its BH1, BH2, and BH3 domains ([@bib46]). This conformation not only prevents Bax targeting to the MOM but also inhibits the binding of regulatory proteins to the hydrophobic pocket.

Although the COOH-terminal TMB of Bax possesses the properties of a transmembrane domain, it is still unknown whether once released from the hydrophobic pocket it also serves as a targeting signal for the MOM. [@bib36] have shown that although the last 21 amino acids of the TMB fused to GFP were insufficient for mitochondrial targeting, they form a mitochondria targeting signal when Ser184 was deleted or mutated to Val or Ala. Ser184 stabilizes the inactive conformation of Bax by forming a hydrogen bond with Asp98 in the hydrophobic pocket ([@bib46]). Therefore, two events may be necessary to target Bax to the MOM via the COOH-terminal TMB: (1) breaking the TMB--pocket interaction, and (2) increasing the hydrophobicity of Ser184 (mimicking the S184A mutation). Alternatively, [@bib6] proposed that an NH~2~-terminal sequence of Bax encompassing amino acids 20--37 mediates MOM targeting. Upon activation, Bax undergoes a conformational change during which it exposes an NH~2~-terminal epitope, but the significance of this exposure is unknown ([@bib23], [@bib24]; [@bib36]). As NH~2~-terminal exposure occurs simultaneously with mitochondrial translocation, it may either unveil an NH~2~-terminal targeting sequence or facilitate the release of the TMB from the hydrophobic pocket. Three proteins have recently been suggested to regulate targeting of Bax to the MOM by binding to the NH~2~ terminus (Ku70; [@bib43]), the COOH terminus (humanin; [@bib21]), or both (14-3-3θ; [@bib38]). The absence of these proteins increased Bax translocation and cytotoxicity but only in the presence of an apoptotic stimulus, indicating that these proteins stabilize Bax in the cytosol but that additional proteins and/or posttranslational modifications are required to trigger its conformational change and mitochondrial translocation.

In this work, we show that mitochondrial translocation of Bax is mediated by the 23 amino acids of the COOH-terminal TMB. Moreover, we define Pro168 in the loop preceding the TMB as a crucial amino acid that couples NH~2~-terminal exposure to the release of the COOH-terminal TMB.

Results
=======

Endogenous Bax is cytosolic and peripherally attached to mitochondria
---------------------------------------------------------------------

Analysis of purified subcellular fractions of HEK293 revealed that endogenous Bax mainly resides in the cytosol and on the MOM (Fig. S1, A and B, available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>). Most of the mitochondrial form was extracted with alkali treatment, indicating that Bax is peripherally attached to mitochondria (Fig. S1 C). Neither cytosolic nor mitochondrial Bax was detected by immunofluorescence with NH~2~-terminal--directed antibody, confirming that its NH~2~-terminal epitope was obstructed (Fig. S1 D; [@bib23], [@bib24]). As previously shown ([@bib19]), Bak behaved differently from Bax as it was not found in the cytosol but instead stably inserted in the mitochondrial membrane (alkali-resistant; Fig. S1, A and C).

Transfected Bax and EGFP-Bax effectively translocate to mitochondria and only residually remain soluble
-------------------------------------------------------------------------------------------------------

Next, we determined the subcellular distribution and proapoptotic activity of overexpressed Bax. Analysis by confocal microscopy showed that 80--90% of HeLa cells transfected with Bax (Fig. 1 A, bottom two rows) or EGFP-Bax (Fig. 1 B, bottom) displayed punctate Bax fluorescence staining, diffuse cytosolic cytochrome *c*, and fragmented nuclei. A similar finding was obtained with Bax-transfected HEK293 cells (Fig. S2, Bax, available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>). The punctate Bax fluorescence was in proximity to, but not overlapping with, mitochondrial markers ([Fig. 1](#fig1){ref-type="fig"} A, Mito Marker). This finding is consistent with recent works demonstrating that in apoptotic cells Bax coalesces into clusters ([@bib37]), which associate with mitochondrial fission sites ([@bib27]). The majority of overexpressed Bax was found on the MOM (Fig. S1 B). Occasionally, both Bax (Fig. 1 A, top two rows) and EGFP-Bax (not depicted) were detected on elongated structures that perfectly colocalized with a mitochondrial marker by confocal microscopy. These cells did not yet exhibit morphological features of apoptosis, suggesting that Bax was in an early stage of activation. Only ∼10% of the EGFP-Bax transfectants displayed a diffuse cytoplasmic staining (Fig. 1 B, top). The expression of cytosolic EGFP-Bax was consistently low, indicating that soluble EGFP-Bax cannot accumulate to high levels (see Figs. S3 and S6A). These data show that upon overexpression, both Bax and EGFP-Bax translocate efficiently to mitochondria and do not require an exogenous apoptotic stimulus.

![**Intracellular localization and cytotoxicity of transfected Bax and EGFP-Bax.** (A) Confocal microscopy of HeLa cells transfected with Bax for 16 h using anti--N-Bax and an antibody against a mitochondrial protein (Mito Marker) for colocalization (Overlay). The fourth row shows an apoptotic cell (nuclear stain DRAQ5) with clustered Bax and cytochrome *c* released. (B) Direct fluorescence of EGFP-Bax in HeLa cells together with the mito marker.](200309013f1){#fig1}

Tailless Bax and EGFP-Bax form cytoplasmic aggregates and are not targeted to mitochondria
------------------------------------------------------------------------------------------

To define the mitochondrial targeting sequence of Bax, we first removed the entire COOH-terminal transmembrane domain including the downstream basic-rich region (TMB) in both Bax and EGFP-Bax ([Fig. 2](#fig2){ref-type="fig"} A). The mutants were transfected into HeLa cells and monitored for subcellular localization by fluorescence analysis ([Fig. 2](#fig2){ref-type="fig"} B). In addition, we determined their cytotoxicity by transfecting them into HEK293 cells in the absence (for EGFP-BaxΔTMB) or presence (for BaxΔTMB) of an EGFP expression plasmid followed by FACS^®^ analysis of EGFP-positive, propidium iodide (PI)--negative cells after 24 h (EGFP survival assay; Fig. S3, available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>). Both ΔTMB mutants lacked proapoptotic activity (Fig. S3), exhibited a cytoplasmic staining ([Fig. 2](#fig2){ref-type="fig"} B), and were primarily found in a cytosolic fraction ([Fig. 3](#fig3){ref-type="fig"} A). However, the mutants also formed aggregates, which did not colocalize with mitochondria ([Fig. 2](#fig2){ref-type="fig"} B), ER, or lysosomes (not depicted). Strikingly, BaxΔTMB was detected with NH~2~-terminal antibodies, suggesting that the NH~2~ terminus was open but not competent for mitochondrial targeting. To test whether or not the NH~2~-terminal amino acids 20--37 could nevertheless contribute to mitochondrial targeting as previously reported ([@bib6]), we exposed this domain by removing the first 20 amino acids (BaxΔN20). This mutant was highly toxic upon transfection into HEK293 cells (see [Fig. 5](#fig5){ref-type="fig"} C), exhibited a punctate mitochondrial staining as wild-type Bax ([Fig. 1](#fig1){ref-type="fig"} A and not depicted), and was effectively targeted to mitochondria in vitro (see [Fig. 8](#fig8){ref-type="fig"} A). However, when we also removed the TMB in the BaxΔN20 mutant (BaxΔN20ΔTMB), the protein became cytoplasmic and nontoxic (unpublished data). These data show that Bax requires the TMB, and not the NH~2~-terminal amino acids 20--37, for mitochondrial targeting. Moreover, through its interaction with the hydrophobic pocket, the TMB seems to protect Bax from inappropriate aggregation in the cytosol.

![**Bax lacking the TMB forms cytoplasmic aggregates.** (A) Schematic structure and amino acid sequences of the COOH-terminal parts (TMB) of Bax and Bak. Pro168 of Bax and Pro187 of Bak are marked in bold and are situated at similar positions in a loop region in the X-domain ahead of the TMB. (B) Confocal microscopy of HeLa cells transfected with BaxΔTMB (using anti--N-Bax) or EGFP-BaxΔTMB (codetection of EGFP and mito marker \[red\]). Note the cytoplasmic aggregates, which do not colocalize with mito marker.](200309013f2){#fig2}

![**Mitochondrial targeting of Bax requires the 23 amino acids of the TMB region.** (A) Anti-GFP Western blots of subcellular fractions from HEK293 cells expressing the indicated EGFP fusion constructs. To test the mitochondrial association of EGFP-23aa-C(Bax), isolated mitochondria were treated with sodium carbonate (pH 12) to remove loosely attached proteins (Att), and the pellet was extracted with detergent (right, Ins). (B) EGFP (green) and anti--mito marker (red) fluorescence analysis of HeLa cells transiently transfected with the indicated EGFP fusion constructs.](200309013f3){#fig3}

The COOH-terminal TMB region is both necessary and sufficient for mitochondrial targeting
-----------------------------------------------------------------------------------------

It has been reported that the last 21 amino acids of the COOH-terminal TMB domain are insufficient for mitochondrial targeting, unless its hydrophobicity is increased by mutating Ser184 to Ala or Val ([@bib36]). Thus, a regulatory mechanism mimicking this mutation may be required to make the COOH terminus competent for mitochondrial targeting. However, we envisaged the possibility that sequences upstream of these 21 amino acids, which still belonged to the TMB, could contribute to this targeting process ([Fig. 2](#fig2){ref-type="fig"} A). Therefore, we fused the last 21, 22, and 23 amino acids of Bax to EGFP and expressed the chimeras in HeLa and HEK293 cells. In agreement with [@bib36], transiently transfected EGFP-21aa-C(Bax) resided primarily in the cytoplasm ([Fig. 3, A and B](#fig3){ref-type="fig"}). Some of the fusion protein was found in membrane fractions, presumably because of the hydrophobicity of the 21 amino acids, but these membranes were not specifically mitochondrial ([Fig. 3](#fig3){ref-type="fig"} A). When the COOH terminus was extended to 22 amino acids, the EGFP-22aa-C(Bax) fusion protein still displayed cytosolic fluorescence staining ([Fig. 3](#fig3){ref-type="fig"} B) and the majority was found in the cytosol and on microsomes upon subcellular fractionation ([Fig. 3](#fig3){ref-type="fig"} A). In contrast, the EGFP-23aa-C(Bax) construct, which includes the entire TMB domain of Bax ([Fig. 2](#fig2){ref-type="fig"} A), specifically colocalized with mitochondrial markers ([Fig. 3](#fig3){ref-type="fig"} B). At least one basic residue was required at the end of the TMB for correct targeting (see supplemental material and Fig. S4, available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>). As expected for a TMB domain that serves as a targeting and membrane insertion device, the EGFP-23aa-C(Bax) localized with and inserted into the MOM ([Fig. 3](#fig3){ref-type="fig"} A). Extending the TMB targeting sequence to its upstream X-domain (EGFP-X-TMB(Bax); [Fig. 2](#fig2){ref-type="fig"} A) did not alter mitochondrial targeting ([Fig. 3, A and B](#fig3){ref-type="fig"}), indicating that the 23 amino acids of the TMB are necessary and sufficient for mitochondrial targeting.

Pro168 regulates NH~2~-terminal exposure and the release of the COOH-terminal TMB targeting sequence
----------------------------------------------------------------------------------------------------

We assumed that the release of the COOH-terminal TMB from its hydrophobic pocket requires a conformational change that is regulated by amino acids in the loop region directly upstream of the α-helical TMB ([Fig. 2](#fig2){ref-type="fig"} A). This loop is solvent-exposed and may be modified or bound by regulatory proteins implicated in the release process ([Fig. 4](#fig4){ref-type="fig"}). All five amino acids within this loop region (X-domain, Phe165--Thr169) were mutated and their intracellular localization was determined after transient transfection of HeLa or HEK293 cells using NH~2~-terminal antibodies. Most point mutations in the loop region did not affect the mitochondrial targeting of Bax, and transfectants had an identical appearance to those overexpressing wild-type Bax (unpublished data). However, when Pro168 was deleted (BaxΔP168) or substituted for Ala ([Fig. 2](#fig2){ref-type="fig"} A, Bax(P168A)), 80--90% of both HeLa ([Fig. 5](#fig5){ref-type="fig"} A) or HEK293 transfectants (Fig. S2) displayed a diffuse cytoplasmic Bax staining, were stretched out, and had intact nuclei. Moreover, the Pro168 mutants were only slightly cytotoxic ([Fig. 5](#fig5){ref-type="fig"} C). Strikingly, both BaxΔP168 and Bax(P168A) were detected with NH~2~-terminal antibodies, indicating that their NH~2~-terminal epitopes were exposed in the cytoplasm. This exposure was confirmed by using the NH~2~-terminal Bax antibody to immunoprecipitate stably expressed FLAG-tagged Bax or Bax(P168A) from HeLa cell extracts ([Fig. 5](#fig5){ref-type="fig"} B). Only low levels of FLAG-Bax could be captured with the antibody, whereas FLAG-Bax(P168A) was effectively immunoprecipitated from the lysate although both proteins were expressed at similar levels ([Fig. 5](#fig5){ref-type="fig"} B). These data show that the BaxΔP168 and Bax(P168A) mutants had the NH~2~-terminal epitope exposed but failed to translocate to mitochondria and induce apoptosis.

![**Modeling of the solution structure of Bax in the region of X-TMB (Pro168).** Molecular modeling of Bax using the Deep View Swiss-PDB viewer ([@bib44]) and based on the Bax NMR solution coordinate data from [@bib46]. Phe165--Trp170 are in a solvent-exposed loop of which Pro168 is at the turning point. Pro168 is in the trans configuration and is close to Trp170, the first amino acid in the TMB targeting sequence.](200309013f4){#fig4}

###### 

**Pro168 and Trp170 mutants of Bax reside in the cytoplasm in an inactive form and have their NH** ~2~ **termini exposed.** (A) Anti--N-Bax and mito marker coimmunofluorescence analysis of HeLa cells transfected with Pro168 and Trp170 mutants of Bax. The yellow mitochondrial staining is due to the strong mitochondrial red staining shining through cytoplasmic green fluorescence. An NH~2~-terminally truncated BaxΔN20/P168A mutant is still cytoplasmic as detected by anti-Bax (aa43--61) immunostaining. (B) Anti--N-Bax immunoprecipitation (IP) from cytosols of HeLa cells stably expressing FLAG-Bax or FLAG-Bax(P168A) followed by anti-FLAG Western blotting. Only FLAG-Bax(P168A) but not FLAG-Bax was immunoprecipitated, although both proteins were expressed at similar levels (Cytosol). (C) Survival assay. Percentage of EGFP-positive/PI-negative cells, determined by FACS^®^, after cotransfection of HEK293 cells with EGFP and either pcDNA3 or the indicated Bax or Bak construct. The values were normalized to pcDNA3/EGFP (co)transfections where maximal survival (100%) is seen. Values are the mean of five independent experiments ± SEM.
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To further substantiate that the release of the COOH-terminal TMB was dependent on Pro168 and not on the exposure of the NH~2~-terminal epitope, we deleted the NH~2~-terminal 20 amino acids in the Bax(P168A) mutant. This double mutant confirmed our results, suggesting that Bax is targeted to the MOM via its COOH-terminal TMB rather than the NH~2~-terminal amino acids 20--37. BaxΔN20/P168A exhibited a diffuse cytoplasmic staining after transfection into HeLa cells ([Fig. 5](#fig5){ref-type="fig"} A) and was as slightly cytotoxic in the HEK293/EGFP survival assay as Bax(P168A) ([Fig. 5](#fig5){ref-type="fig"} C). Thus, Bax requires Pro168 for COOH-terminal unleashment, mitochondrial targeting, and cytotoxicity even when the NH~2~ terminus is deleted.

Proline does not have the ability to form a classical hydrogen bond within the protein backbone. This property imposes some restrictions on the secondary and tertiary structures of proteins defining its role as a helix breaker. If Pro168 were to play a purely structural role in the TMB of Bax, its replacement by another helix-breaking amino acid such as glycine would not be expected to change the mitochondrial targeting and cytotoxic properties of Bax. However, a Bax(P168G) mutant was indistinguishable from BaxΔ168 or Bax(P168A) with respect to survival activity, cytoplasmic retention, and NH~2~-terminal exposure ([Fig. 5, A and C](#fig5){ref-type="fig"}). This was also the case when Pro168 was mutated to Glu, a helix-forming amino acid ([Fig. 5, A and C](#fig5){ref-type="fig"}, Bax(P168E)). These results suggest that the helix-breaking capacity of Pro168 is not involved in Bax COOH-terminal TMB release. To confirm that Pro168 was responsible for the release and not the targeting function of the TMB, we created an EGFP-X-TMB(Bax) (loop-TMB) fusion protein in which Pro168 was substituted for Ala. This EGFP-X(P168A)-TMB(Bax) protein was targeted to mitochondria as efficiently as the EGFP-X-TMB(Bax) construct ([Fig. 3](#fig3){ref-type="fig"} B). Together, our data suggest that Pro168 is not part of the COOH-terminal TMB targeting sequence but is a crucial amino acid for regulating the release of this targeting sequence from the hydrophobic pocket. Most importantly, Pro168 inhibits NH~2~-terminal exposure indicating that it somehow couples the NH~2~ terminus to the loop-TMB region of Bax.

Pro168 mutants of Bax are not aberrantly folded and reside in the cytoplasm in a stable form
--------------------------------------------------------------------------------------------

It is possible that mutations in Pro168 changed the structure of Bax in a way that the protein would aggregate and be rapidly degraded. To exclude this possibility, we determined the size of Bax protein complexes in the cytosol of FLAG-Bax-- and FLAG-Bax(P168A)--transfected HeLa cells by gel filtration analysis. As shown in Fig. S5 A (available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>), endogenous Bax, overexpressed FLAG-Bax, and mutant FLAG-Bax(P168A) were all immunodetected in fractions corresponding to monomeric Bax (20--35 kD). No high molecular mass aggregates were observed for any of the Bax forms. Most importantly, both FLAG-Bax and FLAG-Bax(P168A) oligomerized in the presence of the nonionic detergent NP-40 indicating that they undergo the same conformational change as Bax (Fig. S5 B). In addition, the Pro168 mutants of Bax were stable proteins. The steady-state expression of EGFP-Bax(P168A) and EGFP-Bax(P168G) proteins did not significantly change for 24--48 h after transfection (Fig. S6 A, available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>), nor were the proteins rapidly degraded in the presence of CHX (Fig. S6 B). In contrast, EGFP-Bax protein levels decreased (Fig. S6 B) and were almost lost at 24--48 h after transfection (Fig. S6 A), presumably due to the loss of EGFP-Bax--expressing cells by apoptosis (Figs. S3 and S6 B).

Pro168 mutants of Bax do not translocate to mitochondria after staurosporine treatment
--------------------------------------------------------------------------------------

Apoptotic stimuli such as the kinase inhibitor staurosporine provoke the exposure of the NH~2~-terminal helix α1 and mitochondrial translocation of endogenous cytosolic Bax ([@bib13]). Similarly, staurosporine can trigger the mitochondrial translocation of transfected cytosolic GFP-Bax, and hence promotes apoptosis in cells that express low levels of GFP-Bax ([@bib36]). To investigate the contribution of Pro168 to the staurosporine-induced translocation of GFP-Bax, we generated Pro168 mutants of EGFP-Bax and studied their intracellular localization in mouse embryo fibroblasts (MEFs) in either the presence or absence of 1 μM staurosporine by direct fluorescence ([Fig. 6](#fig6){ref-type="fig"} A). In addition, we tested the apoptotic potential of the EGFP variants in HEK293 cells using FACS^®^ analysis ([Fig. 6](#fig6){ref-type="fig"} B). EGFP alone did not induce apoptosis and was highly expressed in the cytoplasm of both untreated and staurosporine-treated MEFs ([Fig. 6](#fig6){ref-type="fig"}). In contrast, most of the EGFP-Bax transfectants were lost ([Fig. 6](#fig6){ref-type="fig"} B). The few surviving cells contained low levels of cytosolic EGFP-Bax of which all translocated to mitochondria in response to staurosporine ([Fig. 6](#fig6){ref-type="fig"} A). As shown for Bax(P168A) ([Fig. 5](#fig5){ref-type="fig"} C), EGFP-Bax variants in which Pro168 was mutated to Ala or Gly were only mildly toxic ([Fig. 6](#fig6){ref-type="fig"} B) and localized to the cytoplasm ([Fig. 6](#fig6){ref-type="fig"} A, left) and a cytosolic fraction ([Fig. 3](#fig3){ref-type="fig"} A). Strikingly, even after 4 h of staurosporine treatment, the majority of MEFs expressing EGFP-Bax(P168A) and EGFP-Bax(P168G) were still stretched out, contained intact nuclei, and retained the mutant proteins in the cytoplasm ([Fig. 6](#fig6){ref-type="fig"} A, right). Thus, Pro168 is required for the release of the COOH-terminal TMB targeting sequence and the subsequent mitochondrial translocation and cytotoxicity of Bax even in the presence of an external apoptotic stimulus.

![**Pro168 mutants of Bax do not translocate to mitochondria in response to staurosporine.** (A) EGFP (green) and anti--mito marker (red) fluorescence analysis of MEFs transfected with EGFP, EGFP-Bax, or two EGFP-Bax Pro168 mutants either untreated or treated with 1 μM staurosporine (STS) for 4 h. Only 10% of the transfectants express cytosolic EGFP-Bax, whereas \>80% exhibited cytosolic EGFP-Bax(P168A) or EGFP-Bax(P168G) fluorescence. In response to STS, the Pro mutants are retained in the cytosol and the cells remain stretched out. (B) Survival assay of the EGFP fusion proteins in HEK293 cells was performed as described in [Fig. 5](#fig5){ref-type="fig"} C. Values were normalized to EGFP and are the mean of five independent experiments ± SEM.](200309013f6){#fig6}

Pro168 mutants of Bax do not sensitize Bax/Bak DKO cells to drug-induced apoptosis
----------------------------------------------------------------------------------

MEFs deficient in both Bax and Bak (DKO) are highly resistant to drug-induced apoptosis ([@bib49]). If Pro168 mutants of Bax lack proapoptotic activity, they should not be able to sensitize these cells for apoptosis. We stably expressed EGFP-Bax and EGFP-Bax(P168A) to approximately the same levels in Bax/Bak DKO MEFs ([Fig. 7](#fig7){ref-type="fig"} A) and determined the extent of etoposide-induced apoptosis by FACS^®^ analysis of PI-positive cells. As shown in [Fig. 7](#fig7){ref-type="fig"} B, EGFP-Bax resensitized the DKO MEFs for apoptosis to almost the level of wild-type MEFs. In contrast, the EGFP-Bax(P168A)--expressing cells remained resistant to the drug. These data confirm the lack of proapoptotic activity of Bax(P168A).

![**Proapoptotic activity of EGFP-Bax and EGFP-Bax(P168A) in Bax/Bak DKO MEFs.** (A) Bax/Bak-deficient MEFs (DKO) were transduced with retroviruses carrying EGFP-Bax/pLPCx or EGFP-Bax(P168A)/pLPCx plasmids. Mixed populations of cells were FACS^®^-sorted, grown-up, and analyzed for the expression of the respective proteins by anti-GFP Western blotting. As controls, parental MEFs (WT) and DKO MEFs were used. (B) The cells described in A were left untreated or treated with 100 μM etoposide (etopo) for 24 h and stained with 10 μg/ml propidium iodide (PI), and the percentage of PI-positive dead cells was determined by FACS^®^ analysis. The values are taken from fluorescence intensity \>10^2^ of the FACS^®^ histogram and are the mean of four independent experiments ± SEM.](200309013f7){#fig7}

Disruption of the TMB--pocket interaction facilitates in vitro mitochondrial targeting
--------------------------------------------------------------------------------------

To further study the mechanisms of TMB unleashment, we developed an in vitro assay in which the cDNAs of Bax and its mutants were transcribed/translated in rabbit reticulocyte lysates in the presence of \[^35^S\]methionine. The translation mixture was centrifuged to eliminate protein clusters formed during translation, and then added to isolated mitochondria ([Fig. 8](#fig8){ref-type="fig"}). Only ∼20% of Bax synthesized in vitro was targeted to mitochondria. In contrast, Bcl-x~L~, another member of the Bcl-2 family was effectively targeted to mitochondria in vitro (∼60%; [Fig. 8](#fig8){ref-type="fig"}) presumably due to the constitutive exposure of its TMB ([@bib28]). We predicted that if inefficient mitochondrial targeting of Bax were due to the folding of the TMB into the hydrophobic pocket, any disruption of this interaction would enhance mitochondrial association. As expected, a Bax mutant in which the entire pocket was destroyed by deleting helices α5 and α6 (BaxΔ5/6) was as efficiently targeted to mitochondria as Bcl-x~L~ ([Fig. 8](#fig8){ref-type="fig"}). Increased mitochondrial targeting was also observed with Bax(S184A), in which hydrogen bonding between the TMB and the pocket was disrupted, as well as with BaxΔN20, which lacked the first 20 amino acids of Bax ([Fig. 8](#fig8){ref-type="fig"} A). However, the targeting efficiency of these mutants was somewhat lower than for Bcl-x~L~ or BaxΔ5/6. These results suggest that the NH~2~ terminus interacts with the COOH-terminal TMB and that both the removal of the NH~2~ terminus and a breakage of the TMB--pocket interaction facilitates mitochondrial targeting.

![**Targeting of in vitro translated Bax, Bak, and mutants to isolated mitochondria.** Autoradiography of \[^35^S\]methionine-labeled IVTT Bax, Bak, and mutants bound to mitochondria (Mito) or remaining in the supernatant after spinning down the organelles (Sup). Bcl-x~L~ is used as a control because it translocates efficiently to mitochondria in vitro ([@bib28]). In one lane, Bax and Bak were mixed 1:1 before adding to mitochondria (B). This mixture did not enhance Bax translocation. Asterisks denote a Bax protein with an alternative start codon.](200309013f8){#fig8}

We used the in vitro transcription/translation (IVTT) assay to confirm the role of Pro168 in the unleashment and mitochondrial targeting of the TMB of Bax. As variants of Bax with Pro168 mutations were observed to be cytoplasmic, they were expected to be targeted to the mitochondria to a lesser extent than Bax in vitro. Indeed, the amounts of BaxΔP168, Bax(P168A), Bax(P168G), and Bax(P168E) recovered in the mitochondrial pellet were approximately half that of wild-type Bax under the same experimental conditions ([Fig. 8](#fig8){ref-type="fig"} A and not depicted).

Trp170 cooperates with Pro168 for TMB unleashment
-------------------------------------------------

Trp170 is the first amino acid of the TMB mitochondrial targeting sequence ([Fig. 3, A and B](#fig3){ref-type="fig"}). In addition, as seen in the structure of Bax ([Fig. 4](#fig4){ref-type="fig"}), this amino acid is in close contact with Pro168. Therefore, we wondered whether or not Trp170 would assist Pro168 in unleashing the TMB by forming a binding pocket for a putative TMB releasing factor. For that purpose, we generated Bax mutants in which Trp170 was mutated to Ala. As shown in [Fig. 5](#fig5){ref-type="fig"} (A and C), Bax(W170A) had its NH~2~ terminus exposed, was retained in the cytoplasm, and was only mildly cytotoxic after transfection into HEK293 cells. A double mutant of Bax in which both Trp170 and Pro168 were mutated to Ala (Bax(P168A/W170A)) did not induce apoptosis at all ([Fig. 5](#fig5){ref-type="fig"} C). These data indicate that Trp170 is not only part of the TMB targeting sequence but cooperates with Pro168 in regulating NH~2~-terminal exposure and the release of the TMB for mitochondrial targeting.

Proline-directed release of the COOH-terminal TMB does not occur with the related protein Bak
---------------------------------------------------------------------------------------------

As shown in Fig. S1 C, endogenous Bak stably associates with mitochondria in nonapoptotic cells. Bak possesses a Pro residue, Pro187, at a similar position upstream of the TMB as Bax ([Fig. 2](#fig2){ref-type="fig"} A). To determine if mitochondrial targeting of Bak was also dependent on a proline-mediated release of its TMB region, we determined the targeting properties and cytotoxicity of Bak and two Pro187 mutants, Bak(P187G) and Bak(P187E), using the in vitro mitochondrial targeting and the EGFP survival assays. In contrast to Bax, wild-type Bak and the Bak(P187G) and Bak(P187E) mutants were effectively targeted to mitochondria after in vitro translation ([Fig. 8](#fig8){ref-type="fig"} B) and were cytotoxic ([Fig. 5](#fig5){ref-type="fig"} C, bottom). As it was reported that Bak and Bax can form heterodimers or oligomers ([@bib33]), and this formation may disrupt the interaction between the TMB and the hydrophobic pocket of Bax, we further tested if Bak could assist Bax in the TMB unleashment and mitochondrial targeting. However, the extent of Bax translocation to mitochondria remained low when Bax and Bak were cotranslated in vitro ([Fig. 8](#fig8){ref-type="fig"} B). Thus, proline-directed unleashment of the TMB mitochondrial targeting sequence is a regulatory mechanism specific for Bax and does not seem to play a role in the mitochondrial targeting of other Bcl-2 family members such as Bak.

Discussion
==========

Our work provides novel insights into the mechanisms by which Bax translocates to the MOM where it carries out its function. First, we show that in nonapoptotic cells, Bax is not only cytosolic but also peripherally attached to mitochondria. Second, we define the last 23 amino acids of the COOH-terminal TMB domain as both necessary and sufficient for mitochondrial targeting and membrane insertion of Bax. Third, we identify Pro168 as a residue essential for regulating the conformational change of Bax leading to the exposure of the NH~2~ terminus and the release of the TMB from its hydrophobic pocket.

Although Bax is reported to reside exclusively in the cytoplasm of tissue cells ([@bib24]; [@bib30]), we confirm that there is an appreciable amount of the protein peripherally attached to mitochondria in cultured cell lines ([@bib18]; [@bib12]). We suggest that this interaction of Bax with the MOM is not dependent on the TMB targeting sequence for the following reasons: (a) EGFP-TMB is inserted in the MOM rather than loosely attached (alkaline-sensitive; [Fig. 3](#fig3){ref-type="fig"} A); (b) small amounts of endogenous Bax can also reside on other organelle membranes, such as the ER, but in an alkaline-sensitive form ([@bib45]; [@bib54]); and (c) the NH~2~ terminus of alkaline-sensitive mitochondrial Bax is not exposed (Fig. S1 D). These findings suggest that endogenous Bax remains in an inactive conformation on the membranes of unstimulated cells before undergoing the structural changes required for membrane insertion and proapoptotic activity.

It has remained controversial whether or not the translocation of Bax to mitochondria in apoptotic cells is mediated via its NH~2~ or COOH terminus. Recently, an NH~2~-terminal sequence at amino acids 20--37 (α-helix 1) has been reported to act as a mitochondrial targeting signal when fused to GFP ([@bib6]). However, we think that this sequence does not mediate the rapid, early Bax translocation in apoptotic cells. First, it is preceded by an NH~2~-terminal inhibitory domain called apoptosis-regulating targeting domain (ART; amino acids 1--20), which must first be cleaved off to expose the targeting signal ([@bib18]; [@bib16]). Indeed, a calpain-like protease has been shown to mediate ART cleavage ([@bib51]; [@bib16]; [@bib8]; [@bib47]). Because proteolysis is a late event in apoptosis and is prevented by calpain inhibitors without affecting Bax translocation and cell death, it probably serves to accelerate, rather than initiate, Bax translocation and apoptotic signaling through mitochondria ([@bib4]). Second, Bax mutants lacking the ART sequence (BaxΔN20) still depended on the COOH-terminal TMB (not depicted) and Pro168 ([Fig. 5](#fig5){ref-type="fig"} A, BaxΔN20/P168A) for mitochondrial targeting. Third, [@bib6] found that the NH~2~-terminal targeting sequence only mediates an alkaline-sensitive interaction of Bax with the mitochondrial membrane, indicating that the NH~2~ terminus may contribute to the relatively nonspecific interaction of endogenous Bax in nonapoptotic cells. However, based on our results, the 23 amino acids of the COOH-terminal TMB mediate Bax translocation and MOM insertion in apoptotic cells.

In many apoptotic systems, Bax activation has been defined by the exposure of an NH~2~-terminal epitope ([@bib23], [@bib24]; [@bib36]). Although this exposure coincides with Bax translocation to mitochondria, it has remained difficult to explain why it can occur hours before cytochrome *c* release and be reversible upon removal of the apoptotic stimulus ([@bib17]; [@bib48]). These findings indicate that NH~2~-terminal exposure is not the commitment step in Bax activation. Why then is it important and what does it initiate? One possibility is that the NH~2~ terminus interacts with the COOH terminus either directly or via a binding protein as previously proposed ([Fig. 9](#fig9){ref-type="fig"}; [@bib42]). Ku70 has recently been identified as an NH~2~-terminal binding protein of Bax ([@bib43]). Overexpression of Ku70 retains Bax in the cytoplasm, supporting the notion that it may prevent the release of the COOH-terminal TMB. Similarly, a COOH-terminal binding protein, humanin, was shown to prevent Bax translocation after transfection into human cells ([@bib21]). However, neither reducing endogenous Ku70 nor humanin expression sensitized cells for apoptosis or Bax translocation in the absence of an apoptotic stimulus. This finding implies that the loss of NH~2~- or COOH-terminal binding proteins is not sufficient for Bax activation and that an additional, probably energy-requiring step, provided by an apoptotic stimulus is needed to provoke the release of the COOH-terminal TMB ([@bib46]; [Fig. 9](#fig9){ref-type="fig"}). A putative trigger could be a member of the subfamily of BH3-only proteins because these proteins are known to be activated in response to apoptotic stimuli and to bind to the hydrophobic pocket of multidomain Bcl-2 family members with high affinity ([@bib39]). Such a mechanism has been proposed for disengaging the COOH terminus from the hydrophobic pocket of the survival factor Bcl-w ([@bib11]; [@bib22]) and for relieving the COOH-terminal TMB of Bax by the NH~2~-terminal domain ([@bib42]). However, [@bib32] recently presented the structure of Bcl-x~L~ complexed with a fragment of the BH3-only protein Bim and predicted, based on the structural homology between Bcl-x~L~ and Bax, that it is the α-helix 8 rather than the COOH-terminal TMB (α9) that is displaced by the binding of Bim to Bax. Consistent with this view, [@bib46] suggested that the binding of a BH3-only protein to Bax does not confer enough energy for the release of the COOH-terminal TMB.

![**Integrated model of mitochondrial association of Bax in healthy and apoptotic cells.** See Discussion for details.](200309013f9){#fig9}

We provide evidence that Pro168 is a crucial amino acid for regulating both NH~2~-terminal exposure and the release of the COOH-terminal TMB. First, Pro168 mutants of Bax had their NH~2~ termini exposed in the cytoplasm in a nontoxic form. This exposure shows that NH~2~-terminal exposure is neither sufficient for targeting nor for Bax activation and cytotoxicity. It is possible that the Pro mutants were detected with NH~2~-terminal antibodies because endogenous cytoplasmic Bax saturated an NH~2~-terminal binding protein. However, [@bib36] reported that transfection of an S184K mutant of Bax, which was constitutively retained in the cytoplasm, did not have its NH~2~ terminus exposed. Moreover, as shown here, Pro168 mutants even remained in the cytoplasm in response to an apoptotic stimulus such as staurosporine, which is known to provoke Bax translocation. Thus, although COOH-terminal releasing factors (the energy-requiring step) induced by the apoptotic stimulus may have been present, the COOH-terminal TMB was probably not released due to a mutation of Pro168. Our data show that it is not the helix-breaking activity of Pro168 that determines COOH-terminal release, but that a binding protein or posttranslational modification on Pro168 could be the trigger. In this respect, Trp170, which is the first amino acid of the TMB targeting sequence, may contribute to a protein binding site as it is juxtaposed to Pro168 in the cytosolic structure ([Fig. 4](#fig4){ref-type="fig"}), and Bax variants mutated at Trp170 exhibited NH~2~-terminal exposure and nonapoptotic cytoplasmic localization like the Pro168 mutants ([Fig. 5](#fig5){ref-type="fig"}).

What kind of modification or binding activity could operate on Pro168 and Trp170? Prolines can be the target amino acids for prolyl cis/trans isomerases (PPIases). These enzymes accelerate the slow cis-to-trans isomerization of prolines ([@bib15]). Pro368 of diphtheria toxin has been suggested to be a target site for a PPIase and to contribute to the conformational change required for the pore formation of the toxin in the membrane ([@bib25]). Diphtheria toxin is structurally related to Bax ([@bib35]; [@bib46]), and, thus, isomerization of Pro168 may be a crucial step for TMB unleashment, mitochondrial targeting, and membrane insertion. Molecular modeling of the soluble Bax structure revealed that the Pro168 is in its trans configuration ([Fig. 4](#fig4){ref-type="fig"}). Thus, PPIases could favor/accelerate the folding process of Bax after its synthesis on ribosomes. However, our preliminary data suggest that cyclosporine A and rapamycin, inhibitors against the classical PPIases cyclophilin and TOR, respectively, had no effect on Bax translocation and cytotoxicity. This finding does not exclude the participation of another PPIase, such as Pin1, which has recently been shown to regulate the apoptotic activity of p53 ([@bib52]; [@bib53]). Alternatively, Pro168 may bind or release specific proteins after apoptosis stimulation or be the target for a posttranslational modification such as hydroxylation ([@bib29]).

Together, we propose the following model for the mitochondrial translocation and activation of Bax in apoptotic cells ([Fig. 9](#fig9){ref-type="fig"}). In the cytosol of nonapoptotic cells, the NH~2~ terminus is linked to Pro168 (and Trp170) either directly ([Fig. 9](#fig9){ref-type="fig"} B) or via a binding protein ([Fig. 9](#fig9){ref-type="fig"} A) or a posttranslational modification ([Fig. 9](#fig9){ref-type="fig"} C) and prevents COOH-terminal unleashment. In response to an apoptotic stimulus, the interaction between the NH~2~ and COOH terminus is disrupted by the degradation of the binding protein or other modifications. Although this process leads to the exposure of the NH~2~ terminus and sensitizes Bax for activation, it is not sufficient for COOH-terminal release. An additional binding protein or a posttranslational modification is required that acts on Pro168 (and Trp170) and provides the energy to release the COOH-terminal TMB for mitochondrial targeting. Further work is required to identify these regulators of NH~2~-terminal exposure and COOH-terminal release. They will be promising targets for new therapies against diseases in which Bax translocation needs to be stimulated (cancer) or inhibited (neurodegeneration).

Materials and methods
=====================

cDNAs and site-directed mutagenesis
-----------------------------------

All EGFP constructs were made in the pEGFP-C1, -C2, or -C3 vectors (Invitrogen). The cDNAs for FLAG-Bax, the various Bax and Bak mutants, and the EGFP fusion proteins were generated by PCR or standard cut and paste techniques as described in the online supplemental material. All constructs were verified by dideoxynucleotide sequencing.

Immunofluorescence analysis
---------------------------

HeLa cells, HEK293 cells, and MEFs were grown on 17-mm glass coverslips until they reached 70% confluence. The cells were transfected with 0.8 μg of plasmid DNA and 2.4 μl of Superfect for 3 h at 37°C and placed in growth medium. After 16 h, the cells were fixed in 4% PFA and permeabilized with 0.05% saponin and ice-cold acetone. The cells were incubated with anti--N-Bax (detecting amino acids 1--20; Upstate Biotechnology; 1:200) in the presence of either anti--cytochrome *c* (BD Biosciences; 1:50), anti-mitochondria (BP128; The Binding Site Ltd.; 1:300), or anti--hBcl-2 (clone 124; DakoCytomation; 1:100) as colocalization markers for 90 min followed by Alexa Fluor 488 (green)-- and/or Alexa Fluor 546 (red)--conjugated goat anti--rabbit or anti--mouse secondary antibodies (Molecular Probes) for another 60 min. After postfixation in 4% PFA containing 2 μg/ml Hoechst 33342 dye (Molecular Probes) or DRAQ5 (Biostatus Ltd.), the antifading agent Slowfade (Molecular Probes) was added, and the cells were viewed under a laser scanning microscope (model LSM 410; Carl Zeiss MicroImaging, Inc.) using a 488-nm Argon Laser (for green fluorescence) and HeNe-Laser at 543 nm (for red fluorescence) and a HeNe-Laser at 633 nm for DRAQ5. Pictures were processed with Carl Zeiss MicroImaging, Inc. software.

Protein expression, subcellular fractionation, and sodium carbonate extraction
------------------------------------------------------------------------------

HEK293 cells were grown on 150-mm plates until ∼80% confluent, and then transfected with 10 μg of plasmid DNA using 25 μl of Superfect (QIAGEN) as described by the manufacturer. After 3--6 h, the Superfect--DNA complexes were removed and the cells were cultured in fresh medium for another 24--48 h. The cells were homogenized; and fractionation into mitochondria, microsomes, and cytosol was performed by sucrose gradient centrifugation exactly as described in [@bib28]. Submitochondrial fractionation and sodium carbonate extraction of mitochondria were performed as described by [@bib28]. Nuclear fractions are not shown because they could not be reproducibly deprived of cosedimenting or aggregated mitochondria and unlysed cells. For protein stability experiments, 10 μg/ml cycloheximide was added to the cells at 24 h posttransfection for 1--4 h, and total extracts were prepared ([@bib28]).

Western blotting
----------------

30 μg of protein were immunodetected by anti--N-Bax (1:2,000), anti--N-Bak (1:2,000), anti--GFP/JL-8 (Living colors^®^; Invitrogen; 1:1,000), anti-KDEL (StressGen Biotechnologies; 1:1,000), anti-grp78/Bip (StressGen Biotechnologies, 1:1,000), anti--COX-I (Molecular Probes; 1:300), or anti-FLAG (Sigma-Aldrich, 1:1,000) primary antibodies followed by peroxidase-coupled, goat anti--rabbit or anti--mouse secondary antibodies (Sigma-Aldrich). Immunodetection was performed by ECL (Pierce Chemical Co.). Equal protein loading was confirmed by staining the membrane amido black or probing with an antibody against the ubiquitously expressed protein 14-3-3β (Santa Cruz, 1:2,000).

Generation of stable cell lines and immunoprecipitation
-------------------------------------------------------

The FLAG-Bax and FLAG-Bax(P168A) and the EGFP-Bax and EGFP-Bax(P168A) cDNAs were cloned into the low expression retroviral vectors pLxIN and pLPCx, respectively (CLONTECH Laboratories, Inc.). Infectious retroviral virons were produced by transient transfection of the packaging cell line Phoenix ampho (a gift from G.P. Nolan, Stanford University, Stanford, CA). HeLa cells were infected with FLAG-Bax and FLAG-Bax(P168A) viruses in the presence of polybrene, and stable populations were obtained by selection with G418 (2.5 and 5 mg/ml). To avoid clonal artifacts, selected cell populations, instead of clones, were further used. MEFs deficient in both Bax and Bak (DKO cells, provided by S.J. Korsmeyer, Dana-Farber Cancer Institute, Boston, MA) were infected with EGFP-Bax and EGFP-Bax(P168A) viruses and selected by FACS^®^ sorting. Cytosolic fractions were immunoprecipitated using 5 μl anti--N-Bax and 50 μl of 50% (vol/vol) protein A--Sepharose. Immunocomplexes were captured on an end-over-end wheel at 4°C for 2 h and analyzed by anti-FLAG Western blotting as described in the previous paragraph.

IVTT
----

The TNT Quick T7-coupled reticulocyte lysate system (Promega) was used essentially as described by the manufacturer. IVTT and mitochondrial membrane association/insertion was performed exactly as described by [@bib28].

Cell viability assay
--------------------

A cotransfection assay was performed in HEK293 cells. Equal numbers of HEK293 cells were grown in six wells to 70% confluence and cotransfected with 2 μg of the desired cDNA and 0.5 μg EGFP-C2 (CLONTECH Laboratories, Inc.; 4:1 molar ratio) using the lipidic transfection reagent Metafectene (Biontex) as described by the manufacturer. After 24 h, the cells were trypsinized, centrifuged, and resuspended in 1 ml PBS supplemented with 3% FCS and 10 μg/ml PI. Quantitative analysis was performed by analyzing 20,000 cells by FACS^®^ and determining the number of EGFP-positive/PI-negative cell as a percentage of the total. Similar analyses were performed with EGFP-Bax wild-type and mutant constructs 24 h after transfection into HEK293 cells. The percentages obtained for cells transfected with mutant constructs were normalized to that of pcDNA3/EGFP or EGFP.

To test the apoptosis-rescuing effect of Bax and its mutants, wild-type MEFs, Bax/Bak DKO MEFs, and Bax/Bak DKO MEFs stably expressing EGFP-Bax and EGFP-Bax(P168A) were treated with 100 μM etoposide for 24 h and subjected to FACS^®^ analysis in the presence of PI as described in the previous paragraph. Cell death was quantified by counting the PI-positive cells.

Online supplemental material
----------------------------

Details about the role of the two positive charges at the COOH terminus of Bax for mitochondrial targeting, the subcellular localization and cytotoxicity of endogenous and overexpressed Bax and Bak, the cytoplasmic localization of Pro168 mutants of Bax in HEK293 cells, the activity of the TMB-deleted Bax variants, the stability and integrity of the Bax(P168A) protein, as well as the methods for gel filtration analysis and the generation of the various Bax and Bak mutants and the EGFP fusion proteins by PCR or standard cut and paste techniques can be found as supplemental material. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200309013/DC1>.
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